CIMZIA (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
CIMZIA
Date registered
Evaluation commenced
Decision date
Approval time
193 working days (255)
Active ingredients
certolizumab pegol
Registration type
EOI
Indication
Non-radiographic Axial Spondyloarthritis
CIMZIA (solution for injection) is now also indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated Creactive protein (CRP) and/ or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).